Advance Lot Release and In-process Testing of Biologics in QC

FortéBio - A Sartorius Brand

Comprehensive technical and service support for Octet® users in GxP environments

ForteBio’s Octet® systems utilize BLI technology to monitor biomolecular interactions in real time and label-free. They are an ideal replacement for ELISA and HPLC techniques for the quantification of antibodies and recombinant proteins and are especially suitable for product potency lot release assays. The plate-based and fluidic-free format also offers GMP users distinct advantages over comparative SPR based techniques. Octet systems provide higher throughput with the flexibility to run 2 to 96 samples simultaneously and better sample versatility, including the ability to analyze crude samples and more tolerance to diverse sample matrices. In addition, ease of use, low maintenance and high data precision speeds time to results throughout the drug development process.

This whitepaper describes the Octet platform for reliable and routine use under GxP regulations and particular in QC laboratories.

White Paper classification

Applications

biochemical kinetics
interferometry
residue analysis

Product categories

Download white paper now

Advance Lot Release and In-process Testing of Biologics in QC

Comprehensive technical and service support for Octet® users in GxP environments

FortéBio - A Sartorius Brand

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous